Yohan Stephan

Yohan Stephan

Auto-generated profile, based on publicly available information

Yohan Stephan

Institut national de la santé et de la recherche médicale (INSERM), Endothelium, Valvulopathy & Heart Failure (ENVI) U1096, Normandie Université, Rouen, France (M.S., Y.S., L.N., P.M.).

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
IPIxchel Lima Posada
Ixchel Lima Posada
YSYohan Stephan
Yohan Stephan
MSMatthieu SOULIE
Matthieu SOULIE
Roberto Palacios-RamirezRoberto Palacios-Ramirez
Roberto Palacios-Ramirez
BBBenjamin Bonnard
Benjamin Bonnard
PMPaul Mulder
Paul Mulder
The mineralocorticoid receptor (MR) plays an important role in the development of chronic kidney disease (CKD) and associated cardiovascular complications. Antagonizing the overactivation of the MR with MR antagonists (MRA) is a therapeutic option, but their use in patients with CKD is limited due to the associated risk of hyperkalemia. Finerenone is a non-steroidal MRA associated with an improved benefit-risk profile in comparison to steroidal MRAs. In this study, we decided to test whether finerenone improves renal and cardiac function in male hypertensive and diabetic ZSF1 rats as an established preclinical HFpEF model. Finerenone was administered at 10 mg/kg/day for 12 weeks. Cardiac function/hemodynamics were assessed in vivo. ZSF1 rats showed classical signs of CKD with increased BUN, UACR, hypertrophy, and fibrosis of the kidney together with characteristic signs of HFpEF including cardiac fibrosis, diastolic dysfunction, and decreased cardiac perfusion. Finerenone treatment did not impact kidney function but reduced renal hypertrophy and cardiac fibrosis. Interestingly, finerenone ameliorated diastolic dysfunction and cardiac perfusion in ZSF1 rats. In summary, we show for the first time that non-steroidal MR antagonism by finerenone attenuates cardiac diastolic dysfunction and improves cardiac perfusion in a preclinical HFpEF model. These cardiac benefits were found to be largely independent of renal benefits.

18 June 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
IPIxchel Lima Posada
Ixchel Lima Posada
MSMatthieu SOULIE
Matthieu SOULIE
YSYohan Stephan
Yohan Stephan
Roberto Palacios-RamirezRoberto Palacios-Ramirez
Roberto Palacios-Ramirez
BBBenjamin Bonnard
Benjamin Bonnard
FJFrédéric Jaisser
Frédéric Jaisser
Background: The mineralocorticoid receptor plays a significant role in the development of chronic kidney disease (CKD) and associated cardiovascular complications. Classic steroidal mineralocorticoid receptor antagonists are a therapeutic option, but their use in the clinic is limited due to the associated risk of hyperkalemia in patients with CKD. Finerenone is a nonsteroidal mineralocorticoid receptor antagonist that has been recently investigated in 2 large phase III clinical trials (FIDELIO‐DKD [Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease] and FIGARO‐DKD [Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease]), showing reductions in kidney and cardiovascular outcomes. Methods and Results: We tested whether finerenone improves renal and cardiac function in a preclinical nondiabetic CKD model. Twelve weeks after 5/6 nephrectomy, the rats showed classic signs of CKD characterized by a reduced glomerular filtration rate and increased kidney weight, associated with left ventricular (LV) diastolic dysfunction and decreased LV perfusion. These changes were associated with increased cardiac fibrosis and reduced endothelial nitric oxide synthase activating phosphorylation (ser 1177). Treatment with finerenone prevented LV diastolic dysfunction and increased LV tissue perfusion associated with a reduction in cardiac fibrosis and increased endothelial nitric oxide synthase phosphorylation. Curative treatment with finerenone improves nondiabetic CKD‐related LV diastolic function associated with a reduction in cardiac fibrosis and increased cardiac phosphorylated endothelial nitric oxide synthase independently from changes in kidney function. Short‐term finerenone treatment decreased LV end‐diastolic pressure volume relationship and increased phosphorylated endothelial nitric oxide synthase and nitric oxide synthase activity. Conclusions: We showed that the nonsteroidal mineralocorticoid receptor antagonist finerenone reduces renal hypertrophy and albuminuria, attenuates cardiac diastolic dysfunction and cardiac fibrosis, and improves cardiac perfusion in a preclinical nondiabetic CKD model.

1 June 2026 in Hypertension
Verified
Journal Article
Open access
MSMatthieu SOULIE
Matthieu SOULIE
TSTania Sánchez-Bayuela
Tania Sánchez-Bayuela
IPIxchel Lima Posada
Ixchel Lima Posada
YSYohan Stephan
Yohan Stephan
LNLionel Nicol
Lionel Nicol
FJFrédéric Jaisser
Frédéric Jaisser
BACKGROUND: Patients with chronic kidney disease (CKD) are at high risk of cardiovascular complications. We have shown that Ngal (neutrophil gelatinase–associated lipocalin)/lcn2 is involved in aldosterone-induced cardiac remodeling and inflammation. Here, we investigated the role of Ngal in the progression of cardiorenal syndrome. METHODS: CKD was induced in rats via 5/6 nephrectomy in wild-type and Ngal knockout rats. Cardiorenal functions were assessed 3 months after subtotal nephrectomy or sham operation. Cardiac fibroblasts were isolated from wild-type rats and incubated with or without rNgal (recombinant Ngal) and Gal-3 (galectin-3). RESULTS: Cardiac perfusion was less impaired in CKD Ngal knockout than in CKD wild type. Left ventricle interstitial fibrosis was more severe in CKD wild type than in sham but was blunted in CKD Ngal knockout rats. Levels of Gal-3, Col1 (collagen 1), Ccl2 (C-C motif chemokine ligand 2), and IL-6 (interleukin-6) were high in cardiac fibroblasts incubated with rNgal. A similar pattern was observed in cells treated with recombinant Gal-3. Both Ngal and Gal-3 induced activation of the Tlr4 (toll-like receptor 4)-Myd88 (myeloid differentiation primary response 88) pathway. The effects of rNgal were blunted by concomitant treatment with Gal-3 or Tlr4 inhibitors, suggesting that Gal-3 contributes to Ngal-induced cardiac fibrosis and inflammation by activating the Tlr4-Myd88 pathway. In both MEDIA-DHF (Metabolic Road to Diastolic Heart Failure) and BIOSTAT-CHF (Biology Study to Tailored Treatment in Chronic Heart Failure) cohorts, elevated levels of Ngal and Gal-3 were associated with advanced diastolic dysfunction and adverse clinical outcomes, particularly among patients with impaired renal function. CONCLUSIONS: In CKD rats, Ngal was involved in cardiac remodeling via a Gal-3/Tlr4-dependent pathway, increasing inflammation and fibrosis, and correlated to cardiac outcomes in the MEDIA-DHF and BIOSTAT-CHF cohorts.

1 April 2025
Verified
Open access
PDF file
AGAlexandre Geffroy
Alexandre Geffroy
FTFabien Thoumire
Fabien Thoumire
YSYohan Stephan
Yohan Stephan
LPLaurence Puechberty
Laurence Puechberty
BLBenoit Laignel
Benoit Laignel
Depuis septembre 2020 et l’obtention du label Développement durable et responsabilité sociétale (DD&RS), l’Université de Rouen-Normandie (URN) élabore une stratégie de recherche centrée sur l’atteinte des objectifs de développement durable (ODD). À partir de l’étude des conventions et contrats de projets de recherche ainsi que des outils d’analyse des réseaux sociaux, l’URN réalise une cartographie de ses projets de recherche centrés sur la transition, dont le principal objectif est d’identifier des pôles transverses d’expertise scientifique à même de fédérer certains de ses laboratoires autour de projets pluridisciplinaires. L’article vise ainsi à présenter, d’une part, le protocole original déployé et, d’autre part, à préciser qu’une adaptation des ODD, pourtant présentés comme une grille de lecture universelle de la transition, est nécessaire dans le contexte d’une université pluridisciplinaire.

8 April 2026
Verified
Thesis
Closed access
YSYohan Stephan
Yohan Stephan
L’insuffisance cardiaque chronique est une pathologie avec un déclin progressif. Elle peut être cependant entrecoupé par des épisodes d’aggravations aigus appelé décompensation aiguë de l’insuffisance cardiaque chronique. Elle est la première cause d’hospitalisation non planifiée chez les patients de plus de 65 ans. Ces épisodes sont caractérisés par une diminution brutale de la fonction cardiaque suivi par une récupération incomplète de cette dernière. Ces épisodes entrainent un mauvais pronostic pour les patients déclenchant ces épisodes. Les mécanismes cellulaires et moléculaires impliqués sont actuellement très peu connus et très peu étudiés. Cependant, depuis 2016, il existe un modèle murin innovant mimant parfaitement des deux phases caractéristiques de la décompensation aiguë de l’insuffisance cardiaque développé au laboratoire. La vasopressine, ou hormone anti-diurétique, est une hormone produite par l’hypothalamus et ayant une action de vasoconstriction et de rétention d’eau via les aquaporines de type 2. Depuis de nombreuses années, il a été démontré que le taux plasmatique de vasopressine est augmenté dans l’insuffisance cardiaque congestive. L’hypothèse de notre travail de recherche correspond à une importante implication de la vasopressine dans les épisodes de décompensation au vu de ces fonctions délétères. Pour cela, nous avons décidé de cibler la vasopressine par deux stratégies thérapeutiques, par des antagonistes aux récepteurs de la vasopressine et par un aptamère, dans notre modèle de décompensation aiguë de l’insuffisance cardiaque chronique.

16 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
sara Hoummadysara Hoummady
sara Hoummady
ABAudrey Besegher
Audrey Besegher
LRLena Rousseau
Lena Rousseau
SJSarah Jeannin
Sarah Jeannin
TBThierry Bedossa
Thierry Bedossa
NRNancy Rebout
Nancy Rebout
Assessment of the predictive ability of the frailty phenotype and the frailty index for all-cause mortality and owner-reported health deterioration in a prospective cohort of companion dogs using exclusively owner-completed online questionnaires. 107 dogs aged 6 years and more were enrolled in the CaniAge cohort with complete baseline and seven-month follow-up data based on owner-completed online questionnaires adapted from validated tools. Frailty was conceptualized using three distinct tools derived from baseline-data: a continuous Frailty Index, a binarised Frailty Index, and a Frailty Phenotype. Two outcomes were evaluated at follow-up 7 months after inclusion using logistic and cox models: owner-reported all-cause mortality and owner-reported health deterioration among surviving dogs.11.2% had died and 24.2% of the surviving dogs had experienced owner-perceived health deterioration during the follow-up period. The continuous Frailty Index (OR = 1.27, 95% CI: 1.08-1.52; P < 0.01), and the Frailty Phenotype (OR = 8.37, 95% CI: 1.60–43.5; P < 0.001) remained significantly associated with mortality, after adjustment for age. For health deterioration, after age adjustment, the bFI was independently associated, with a deterioration of health within 7 months (OR = 17.52, 95% CI: 2.53–351.74, P = 0.01), as was physical frailty (OR = 10.10, 95% CI: 1.24–212.16, P = 0.05) and the cFI (OR = 1.13, 95% CI: 1.01–1.27, P = 0.04).Owner-completed frailty questionnaires predicted both mortality and health deterioration in senior companion dogs. The continuous Frailty Index was the most robust prognostic instrument across all outcomes